Xellar Biosystems closes $50 million Series A and A+ financing

The Boston biotech said the funding will expand its organ-on-chip, automation, imaging, multi-omics and AI platform for human-relevant biological data and virtual cell development.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.